anti-CD117 CAR-T cells (Poseida Therapeutics)

N/A

Report date: 2025/08/28 20:00:09

Base Information

Drug Nameanti-CD117 CAR-T cells (Poseida Therapeutics)
Drug Alias NameCAR T-cell therapy (Poseida Therapeutics)
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionStem cell growth factor receptor inhibitors
TargetsStem cell growth factor receptor
Therapy Area/IndicationsLeukemia, Myeloid, AcuteHematopoietic stem cell transplantation (HSCT)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesPoseida Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesShanghai YaKe Biotechnology Co LtdPoseida Therapeutics IncZhejiang University
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, AcuteHematopoietic stem cell transplantation (HSCT)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A